Rock Point Advisors LLC Buys Shares of 23,163 Boston Scientific Corporation $BSX

Rock Point Advisors LLC bought a new stake in Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 23,163 shares of the medical equipment provider’s stock, valued at approximately $2,209,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Claret Asset Management Corp lifted its holdings in shares of Boston Scientific by 4.4% during the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock worth $234,000 after acquiring an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of Boston Scientific by 5.1% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 103 shares during the period. Kera Capital Partners Inc. lifted its holdings in shares of Boston Scientific by 3.3% during the 3rd quarter. Kera Capital Partners Inc. now owns 3,407 shares of the medical equipment provider’s stock worth $333,000 after acquiring an additional 109 shares during the period. Outfitters Financial LLC lifted its holdings in shares of Boston Scientific by 0.5% during the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after acquiring an additional 110 shares during the period. Finally, Fayez Sarofim & Co lifted its holdings in shares of Boston Scientific by 2.1% during the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock worth $520,000 after acquiring an additional 111 shares during the period. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Daiwa Securities Group lowered shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Barclays cut their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a report on Thursday, April 23rd. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. TD Cowen cut their price objective on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Finally, Morgan Stanley cut their price objective on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Stock Up 1.4%

BSX stock opened at $54.12 on Wednesday. Boston Scientific Corporation has a twelve month low of $53.15 and a twelve month high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $80.43 billion, a P/E ratio of 22.64, a PEG ratio of 0.98 and a beta of 0.62. The firm has a 50 day simple moving average of $64.65 and a 200-day simple moving average of $82.68.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts predict that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.